2016 Fiscal Year Final Research Report
A new treatment strategy targeting to DNA repair pathway of castration resistant prostate cancer
| Project/Area Number |
15K20108
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Keywords | 去勢抵抗性前立腺癌 / ドセタキセル抵抗性 / PARP阻害剤 / DNA修復機構 |
|---|
| Outline of Final Research Achievements |
In this study, we explored the efficacy of a PARP inhibitor for docetaxel resistant prostate cancer cell line: C4-2AT6. C4-2AT6 cells revealed combined administration of PARP inhibitor and docetaxel had a significant and synergistically high apoptosis inducing effect. In a castrated mice xenograft model, combined PARP inhibitor and docetaxel also showed high anti-tumor effect. These results suggested that inhibition of DNA repair pathway was able to overcome docetaxel resistance in human docetaxel resistant prostate cancer.
|
| Free Research Field |
医歯薬学
|
